vs
Side-by-side financial comparison of Chemours Co (CC) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
Chemours Co is the larger business by last-quarter revenue ($1.3B vs $1.1B, roughly 1.2× PERRIGO Co plc). Chemours Co runs the higher net margin — -3.5% vs -127.8%, a 124.3% gap on every dollar of revenue. On growth, Chemours Co posted the faster year-over-year revenue change (-2.1% vs -2.5%). PERRIGO Co plc produced more free cash flow last quarter ($148.6M vs $92.0M). Over the past eight quarters, PERRIGO Co plc's revenue compounded faster (1.3% CAGR vs -1.2%).
The Chemours Company is an American chemical company that was founded in July 2015 as a spin-off from DuPont. It has its corporate headquarters in Wilmington, Delaware, United States. Chemours is the manufacturer of Teflon, the brand name of polytetrafluoroethylene (PTFE), known for its anti-stick properties. It also produces titanium dioxide and refrigerant gases.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
CC vs PRGO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $1.1B |
| Net Profit | $-47.0M | $-1.4B |
| Gross Margin | 11.7% | 32.6% |
| Operating Margin | — | -116.0% |
| Net Margin | -3.5% | -127.8% |
| Revenue YoY | -2.1% | -2.5% |
| Net Profit YoY | -261.5% | -3093.9% |
| EPS (diluted) | $-0.32 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3B | $1.1B | ||
| Q3 25 | $1.5B | $1.0B | ||
| Q2 25 | $1.6B | $1.1B | ||
| Q1 25 | $1.4B | $1.0B | ||
| Q4 24 | $1.4B | $1.1B | ||
| Q3 24 | $1.5B | $1.1B | ||
| Q2 24 | $1.6B | $1.1B | ||
| Q1 24 | $1.4B | $1.1B |
| Q4 25 | $-47.0M | $-1.4B | ||
| Q3 25 | $46.0M | $7.5M | ||
| Q2 25 | $-380.0M | $-8.4M | ||
| Q1 25 | $-5.0M | $-6.4M | ||
| Q4 24 | $-13.0M | $-44.4M | ||
| Q3 24 | $-32.0M | $-21.0M | ||
| Q2 24 | $60.0M | $-108.4M | ||
| Q1 24 | $54.0M | $2.0M |
| Q4 25 | 11.7% | 32.6% | ||
| Q3 25 | 15.6% | 36.1% | ||
| Q2 25 | 17.2% | 34.4% | ||
| Q1 25 | 17.3% | 37.6% | ||
| Q4 24 | 19.4% | 33.9% | ||
| Q3 24 | 19.0% | 37.2% | ||
| Q2 24 | 19.8% | 37.0% | ||
| Q1 24 | 20.9% | 33.1% |
| Q4 25 | — | -116.0% | ||
| Q3 25 | 2.5% | 7.0% | ||
| Q2 25 | -15.4% | 4.3% | ||
| Q1 25 | — | 4.5% | ||
| Q4 24 | -0.1% | 10.0% | ||
| Q3 24 | -2.1% | 7.4% | ||
| Q2 24 | 4.4% | -2.5% | ||
| Q1 24 | 5.1% | -5.1% |
| Q4 25 | -3.5% | -127.8% | ||
| Q3 25 | 3.1% | 0.7% | ||
| Q2 25 | -23.5% | -0.8% | ||
| Q1 25 | -0.4% | -0.6% | ||
| Q4 24 | -1.0% | -3.9% | ||
| Q3 24 | -2.1% | -1.9% | ||
| Q2 24 | 3.9% | -10.2% | ||
| Q1 24 | 4.0% | 0.2% |
| Q4 25 | $-0.32 | $-10.23 | ||
| Q3 25 | $0.31 | $0.05 | ||
| Q2 25 | $-2.53 | $-0.06 | ||
| Q1 25 | $-0.03 | $-0.05 | ||
| Q4 24 | $-0.07 | $-0.32 | ||
| Q3 24 | $-0.22 | $-0.15 | ||
| Q2 24 | $0.39 | $-0.79 | ||
| Q1 24 | $0.36 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $670.0M | — |
| Total DebtLower is stronger | $4.1B | — |
| Stockholders' EquityBook value | $250.0M | $2.9B |
| Total Assets | $7.4B | $8.5B |
| Debt / EquityLower = less leverage | 16.40× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $670.0M | — | ||
| Q3 25 | $613.0M | $432.1M | ||
| Q2 25 | $502.0M | $454.2M | ||
| Q1 25 | $464.0M | $409.9M | ||
| Q4 24 | $713.0M | $558.8M | ||
| Q3 24 | $596.0M | $1.5B | ||
| Q2 24 | $604.0M | $542.8M | ||
| Q1 24 | $746.0M | $658.5M |
| Q4 25 | $4.1B | — | ||
| Q3 25 | $4.1B | — | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $4.0B | — | ||
| Q2 24 | $4.0B | — | ||
| Q1 24 | $4.0B | — |
| Q4 25 | $250.0M | $2.9B | ||
| Q3 25 | $274.0M | $4.4B | ||
| Q2 25 | $228.0M | $4.5B | ||
| Q1 25 | $566.0M | $4.4B | ||
| Q4 24 | $571.0M | $4.3B | ||
| Q3 24 | $643.0M | $4.6B | ||
| Q2 24 | $714.0M | $4.5B | ||
| Q1 24 | $753.0M | $4.7B |
| Q4 25 | $7.4B | $8.5B | ||
| Q3 25 | $7.5B | $10.1B | ||
| Q2 25 | $7.5B | $10.1B | ||
| Q1 25 | $7.4B | $9.8B | ||
| Q4 24 | $7.5B | $9.6B | ||
| Q3 24 | $7.5B | $11.2B | ||
| Q2 24 | $7.2B | $10.4B | ||
| Q1 24 | $8.0B | $10.6B |
| Q4 25 | 16.40× | — | ||
| Q3 25 | 14.96× | — | ||
| Q2 25 | 17.99× | — | ||
| Q1 25 | 7.18× | — | ||
| Q4 24 | 7.11× | — | ||
| Q3 24 | 6.20× | — | ||
| Q2 24 | 5.53× | — | ||
| Q1 24 | 5.27× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $137.0M | $175.4M |
| Free Cash FlowOCF − Capex | $92.0M | $148.6M |
| FCF MarginFCF / Revenue | 6.9% | 13.4% |
| Capex IntensityCapex / Revenue | 3.4% | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $51.0M | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $137.0M | $175.4M | ||
| Q3 25 | $146.0M | $51.7M | ||
| Q2 25 | $93.0M | $75.9M | ||
| Q1 25 | $-112.0M | $-64.5M | ||
| Q4 24 | $138.0M | $312.6M | ||
| Q3 24 | $139.0M | $42.2M | ||
| Q2 24 | $-620.0M | $9.5M | ||
| Q1 24 | $-290.0M | $-1.4M |
| Q4 25 | $92.0M | $148.6M | ||
| Q3 25 | $105.0M | $29.8M | ||
| Q2 25 | $50.0M | $56.7M | ||
| Q1 25 | $-196.0M | $-90.0M | ||
| Q4 24 | $29.0M | $274.9M | ||
| Q3 24 | $63.0M | $15.1M | ||
| Q2 24 | $-693.0M | $-18.9M | ||
| Q1 24 | $-392.0M | $-26.5M |
| Q4 25 | 6.9% | 13.4% | ||
| Q3 25 | 7.0% | 2.9% | ||
| Q2 25 | 3.1% | 5.4% | ||
| Q1 25 | -14.3% | -8.6% | ||
| Q4 24 | 2.1% | 24.2% | ||
| Q3 24 | 4.2% | 1.4% | ||
| Q2 24 | -44.6% | -1.8% | ||
| Q1 24 | -28.8% | -2.4% |
| Q4 25 | 3.4% | 2.4% | ||
| Q3 25 | 2.7% | 2.1% | ||
| Q2 25 | 2.7% | 1.8% | ||
| Q1 25 | 6.1% | 2.4% | ||
| Q4 24 | 8.0% | 3.3% | ||
| Q3 24 | 5.0% | 2.5% | ||
| Q2 24 | 4.7% | 2.7% | ||
| Q1 24 | 7.5% | 2.3% |
| Q4 25 | — | — | ||
| Q3 25 | 3.17× | 6.89× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -10.33× | — | ||
| Q1 24 | -5.37× | -0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CC
| Titanium Technologies | $563.0M | 42% |
| Thermal And Specialized Solutions | $443.0M | 33% |
| Advanced Performance Materials | $312.0M | 23% |
| Other Non-Reportable Segment | $12.0M | 1% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
